N-acetylaspartylglutamate (NAAG) and N-acetylaspartate (NAA) in patients with schizophrenia

Schizophrenia Bulletin

Volumn 39, Issue 1, 2013, Pages 197-205

  Jessen, Frank ^a,b   Fingerhut, Natascha ^a   Sprinkart, Alois M ^a   Kühn, Kai Uwe ^c   Petrovsky, Nadine ^a   Maier, Wolfgang ^a,b   Schild, Hans H ^a   Block, Wolfgang ^a   Wagner, Michael ^a   Träber, Frank ^a  

^a UNIVERSITY OF BONN   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

anterior cingulate gyrus; frontal lobe; magnetic resonance spectroscopy; N acetylasp artylglutamate; N acetylaspartate; schizophrenia

Indexed keywords

N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID;

ADULT; ANTERIOR CINGULATE; ARTICLE; ATTENTION; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; EPISODIC MEMORY; FEMALE; FRONTAL LOBE; HUMAN; IN VIVO STUDY; MALE; MENTAL DISEASE; NEGATIVE SYNDROME; NUCLEAR MAGNETIC RESONANCE SCANNER; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA;

ADULT; ASPARTIC ACID; DIPEPTIDES; FEMALE; FUNCTIONAL LATERALITY; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEUROPSYCHOLOGICAL TESTS; PREFRONTAL CORTEX; PROTONS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 84871841149     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbr127     Document Type: Article

References (39)

1. Paz RD, Tardito S, Atzori M, Tseng KY. Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur Neuropsychopharmacol. 2008;18:773-786.
2. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007;13:1102-1107.
3. Wroblewska B, Wroblewski JT, Pshenichkin S, Surin A, Sullivan SE, Neale JH. N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J Neurochem. 1997;69:174-181.
4. Cartmell J, Adam G, Chaboz S, et al. Characterization of [3H]-(2S,2'R,3'R)-2-(2',3'-dicarboxy-cyclopropyl)glycine ([3H]-DCG IV) binding to metabotropic mGlu2 receptor-transfected cell membranes. Br J Pharmacol. 1998;123:497-504.
5. Olszewski RT, Bukhari N, Zhou J, et al. NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J Neurochem. 2004;89:876-885.
6. Olszewski RT, Wegorzewska MM, Monteiro AC, et al. Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors. Biol Psychiatry. 2008;63:86-91.
7. Zhou J, Neale JH, Pomper MG, Kozikowski AP. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov. 2005;4:1015-1026.
8. Tsai G, Passani LA, Slusher BS, et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry. 1995;52:829-836.
9. Nudmamud S, Reynolds LM, Reynolds GP. N-acetylaspartate and N-Acetylaspartylglutamate deficits in superior temporal cortex in schizophrenia and bipolar disorder: a postmortem study. Biol Psychiatry. 2003;53:1138-1141.
10. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 2000;13:129-153.
11. Bustillo JR, Rowland LM, Mullins P, et al. (1)H-MRS at 4 tesla in minimally treated early schizophrenia. Mol Psychiatry. 2010;15:629-636.
12. Jessen F, Scherk H, Träber F, et al. Proton magnetic resonance spectroscopy in subjects at risk for schizophrenia. Schizophr Res. 2006;87:81-88.
13. Steen RG, Hamer RM, Lieberman JA. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and metaanalysis. Neuropsychopharmacology. 2005;30:1949-1962.
14. Pan JW, Takahashi K. Interdependence of N-acetyl aspartate and high-energy phosphates in healthy human brain. Ann Neurol. 2005;57:92-97.
15. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol. 2007;81:89-131.
16. Pouwels PJ, Frahm J. Differential distribution of NAA and NAAG in human brain as determined by quantitative localized proton MRS. NMR Biomed. 1997;10:73-78.
17. Edden RA, Pomper MG, Barker PB. In vivo differentiation of N-acetyl aspartyl glutamate from N-acetyl aspartate at 3 Tesla. Magn Reson Med. 2007;57:977-982.
18. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
19. Helmstaedter C, Lendt M, Lux S. Verbaler Lern-und Merkfähigkeitstest (VLMT).Gö ttingen, Germany: Beltz; 2001.
20. Tewes U. Hamburg-Wechsler-Intelligenztest für Erwachsene, Revision 1991 (HAWIE-R). Bern, Switzerland: Huber; 1991.
21. Härting C, Neufeld H, Kessler J, et al. Die Wechsler Memory Scale-Revised (WMS-R). Deutsche Version. Gö ttingen, Germany: Hogrefe; 2000.
22. Gold JM, Carpenter C, Randolph T, Weinberger D. Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry. 1997;54:159-165.
23. Reitan RM. Trail Making Test (TMT). Weinheim, Germany: Beltz; 1979.
24. Naressi A, Couturier C, Devos JM, et al. Java-based graphical user interface for the MRUI quantitation package. MAGMA. 2001;12:141-152.
25. Ratiney H, Sdika M, Coenradie Y, et al. Time-domain semiparametric estimation based on a metabolite basis set. NMR Biomed. 2005;18:1-13.
26. Träber F, Block W, Lamerichs R, Gieseke J, Schild HH. 1H metabolite relaxation times at 3.0 tesla: measurements of T1 and T2 values in normal brain and determination of regional differences in transverse relaxation. J Magn Reson Imaging. 2004;19:537-545.
27. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson. 1997;129: 35-43.
28. Ghose S, Gleason KA, Potts BW, Lewis-Amezcua K, Tamminga CA. Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action? Am J Psychiatry. 2009;166:812-820.
29. Guilarte TR, Hammoud DA, McGlothan JL, et al. Dysregulation of glutamate carboxypeptidase II in psychiatric disease. Schizophr Res. 2008;99:324-332.
30. Tsai SJ. Central N-acetyl aspartylglutamate deficit: a possible pathogenesis of schizophrenia. Med Sci Monit. 2005;11:HY39-H45.
31. Arun P, Madhavarao CN, Moffett JR, Namboodiri AM. Antipsychotic drugs increase N-acetylaspartate and Nacetylaspartylglutamate in SH-SY5Y human neuroblastoma cells. J Neurochem. 2008;106:1669-1680.
32. Fricker AC, Mok MH, de la Flor R, et al. Effects of Nacetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR. Neuropharmacology. 2009;56:1060-1067.
33. Wang K, Fan J, Dong Y, Wang CQ, Lee TM, Posner MI. Selective impairment of attentional networks of orienting and executive control in schizophrenia. Schizophr Res. 2005;78:235-241.
34. Camchong J, Dyckman KA, Austin BP, Clementz BA, McDowell JE. Common neural circuitry supporting volitional saccades and its disruption in schizophrenia patients and relatives. Biol Psychiatry. 2008;64:1042-1050.
35. Tayoshi S, Sumitani S, Taniguchi K, et al. Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS). Schizophr Res. 2009;108:69-77.
36. Lutkenhoff ES, van Erp TG, Thomas MA, et al. Proton MRS in twin pairs discordant for schizophrenia. Mol Psychiatry. 2010;15:308-318.
37. Théberge J, Al-Semaan Y, Williamson PC, et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry. 2003;160:2231-2233.
38. Olbrich HM, Valerius G, Rüsch N, et al. Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy study. World J Biol Psychiatry. 2008;9:59-63.
39. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30:672-679.